WallStreetZenWallStreetZen

NASDAQ: KLRS
Kalaris Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their KLRS stock forecasts and price targets.

Forecast return on equity

Is KLRS forecast to generate an efficient return?

Company
-96.62%
Industry
158.69%
Market
89.3%
KLRS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KLRS forecast to generate an efficient return on assets?

Company
-59.87%
Industry
40.47%
KLRS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KLRS earnings per share forecast

What is KLRS's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$8.00
Avg 2 year Forecast
-$9.25
Avg 3 year Forecast
$1.90

KLRS revenue forecast

What is KLRS's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$80.0M
Avg 2 year Forecast
$20.0M

KLRS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KLRS$2.62N/AN/A
CBUS$1.41$21.25+1,407.09%Strong Buy
ADVM$2.32$19.75+751.29%Buy
VRCA$0.52N/AN/A
DTIL$4.30$47.00+993.02%Buy
View Top Biotech Stocks

Kalaris Therapeutics Stock Forecast FAQ

What is KLRS's earnings growth forecast for 2025-2027?

(NASDAQ: KLRS) Kalaris Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.31%.

Kalaris Therapeutics's earnings in 2025 is -$38,666,000.On average, 1 Wall Street analyst forecast KLRS's earnings for 2025 to be -$149,619,344, with the lowest KLRS earnings forecast at -$149,619,344, and the highest KLRS earnings forecast at -$149,619,344. On average, 1 Wall Street analyst forecast KLRS's earnings for 2026 to be -$172,997,367, with the lowest KLRS earnings forecast at -$172,997,367, and the highest KLRS earnings forecast at -$172,997,367.

In 2027, KLRS is forecast to generate $35,534,594 in earnings, with the lowest earnings forecast at $35,534,594 and the highest earnings forecast at $35,534,594.

If you're new to stock investing, here's how to buy Kalaris Therapeutics stock.

What is KLRS's revenue growth forecast for 2027-2029?

(NASDAQ: KLRS) Kalaris Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.9%.

Kalaris Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast KLRS's revenue for 2027 to be $1,496,193,440, with the lowest KLRS revenue forecast at $1,496,193,440, and the highest KLRS revenue forecast at $1,496,193,440.

In 2029, KLRS is forecast to generate $374,048,360 in revenue, with the lowest revenue forecast at $374,048,360 and the highest revenue forecast at $374,048,360.

What is KLRS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: KLRS) forecast ROA is -59.87%, which is lower than the forecast US Biotechnology industry average of 40.47%.

What is KLRS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: KLRS) Kalaris Therapeutics's current Earnings Per Share (EPS) is -$8.27. On average, analysts forecast that KLRS's EPS will be -$8.00 for 2025, with the lowest EPS forecast at -$8.00, and the highest EPS forecast at -$8.00. On average, analysts forecast that KLRS's EPS will be -$9.25 for 2026, with the lowest EPS forecast at -$9.25, and the highest EPS forecast at -$9.25. In 2027, KLRS's EPS is forecast to hit $1.90 (min: $1.90, max: $1.90).

What is KLRS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: KLRS) forecast ROE is -96.62%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.